Martingale Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Martingale Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-40,100	Closed	-$134K	–	802
2023 Q1	$134K	Sell	40,100 -176,185	-81%	-$715K	﹤0.01%	798
2022 Q4	$1.04M	Sell	216,285 -14,079	-6%	-$71.2K	0.02%	440
2022 Q3	$1.31M	Buy	230,364 +84,140	+58%	+$644K	0.03%	359
2022 Q2	$1.04M	Buy	146,224 +96	+0.1%	+$655	0.02%	456
2022 Q1	$1.06M	Buy	146,128 +49,051	+51%	+$333K	0.02%	470
2021 Q4	$868K	Buy	97,077 +62,373	+180%	+$972K	0.01%	531
2021 Q3	$1.22M	Buy	+34,704	New	+$963K	0.02%	466

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's AVIR Position: Q2 2023 in Review

Martingale Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 40,100 shares — an estimated $134K sold.

Martingale Asset Management first reported a position in AVIR in Q3 2021 and held it in 7 quarters. The position peaked at $1.31M in Q3 2022. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

Martingale Asset Management reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Martingale Asset Management sold 40,100 Atea Pharmaceuticals shares in Q2 2023, an estimated $134K.
Martingale Asset Management first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Martingale Asset Management's Atea Pharmaceuticals position peaked at $1.31M in Q3 2022.
133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Martingale Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.